Browsing by Subject "Analgesics"

Now showing 1 - 10 of 15
  • Thumbnail Image
    Item
    Achieving balance in federal and state pain policy: a guide to evaluation (Evaluation guide 2006). [Part 1]
    (2006-09) University of Wisconsin. School of Medicine and Public Health. Pain & Policy Studies Group.
    Assesses federal and state policies regarding the use of controlled substances for pain management, palliative care and end-of-life care. Part 1 contains Sections I - VII of the report, and the federal profile of Section VIII. Part 2 contains state profiles for Alabama - Illinois. Part 3 contains state profiles for Indiana - Michigan. Part 4 contains state profiles for Minnesota - South Dakota. Part 5 contains state profiles for Tennessee - Wyoming, Section IX and the appendices.
  • Thumbnail Image
    Item
    Achieving balance in federal and state pain policy: a guide to evaluation (Evaluation guide 2006). [Part 2]
    (2006-09) University of Wisconsin. School of Medicine and Public Health. Pain & Policy Studies Group.
    Assesses federal and state policies regarding the use of controlled substances for pain management, palliative care and end-of-life care. Part 1 contains Sections I - VII of the report, and the federal profile of Section VIII. Part 2 contains state profiles for Alabama - Illinois. Part 3 contains state profiles for Indiana - Michigan. Part 4 contains state profiles for Minnesota - South Dakota. Part 5 contains state profiles for Tennessee - Wyoming, Section IX and the appendices.
  • Thumbnail Image
    Item
    Achieving balance in federal and state pain policy: a guide to evaluation (Evaluation guide 2006). [Part 3]
    (2006-09) University of Wisconsin. School of Medicine and Public Health. Pain & Policy Studies Group.
    Assesses federal and state policies regarding the use of controlled substances for pain management, palliative care and end-of-life care. Part 1 contains Sections I - VII of the report, and the federal profile of Section VIII. Part 2 contains state profiles for Alabama - Illinois. Part 3 contains state profiles for Indiana - Michigan. Part 4 contains state profiles for Minnesota - South Dakota. Part 5 contains state profiles for Tennessee - Wyoming, Section IX and the appendices.
  • Thumbnail Image
    Item
    Achieving balance in federal and state pain policy: a guide to evaluation (Evaluation guide 2006). [Part 4]
    (2006-09) University of Wisconsin. School of Medicine and Public Health. Pain & Policy Studies Group.
    Assesses federal and state policies regarding the use of controlled substances for pain management, palliative care and end-of-life care. Part 1 contains Sections I - VII of the report, and the federal profile of Section VIII. Part 2 contains state profiles for Alabama - Illinois. Part 3 contains state profiles for Indiana - Michigan. Part 4 contains state profiles for Minnesota - South Dakota. Part 5 contains state profiles for Tennessee - Wyoming, Section IX and the appendices.
  • Thumbnail Image
    Item
    Achieving balance in federal and state pain policy: a guide to evaluation (Evaluation guide 2006). [Part 5]
    (2006-09) University of Wisconsin. School of Medicine and Public Health. Pain & Policy Studies Group.
    Assesses federal and state policies regarding the use of controlled substances for pain management, palliative care and end-of-life care. Part 1 contains Sections I - VII of the report, and the federal profile of Section VIII. Part 2 contains state profiles for Alabama - Illinois. Part 3 contains state profiles for Indiana - Michigan. Part 4 contains state profiles for Minnesota - South Dakota. Part 5 contains state profiles for Tennessee - Wyoming, Section IX and the appendices.
  • Thumbnail Image
    Item
    Association of Cannabis Use With Nausea and Vomiting of Pregnancy
    (Wolters Kluwer, 2022) Metz, Torri D.; Allshouse, Amanda A.; McMillin, Gwendolyn A.; Silver, Robert M.; Smid, Marcela C.; Haas, David M.; Simhan, Hyagriv N.; Saade, George R.; Grobman, William A.; Parry, Samuel; Chung, Judith H.; Jarlenski, Marian P.; Obstetrics and Gynecology, School of Medicine
    Our objective was to evaluate whether cannabis use was associated with nausea and vomiting in early pregnancy. Participants from nuMoM2b (Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be) enrolled from October 2010 through September 2013 with a PUQE (Pregnancy-Unique Quantification of Emesis) questionnaire and an available stored urine sample from the first study visit (median gestational age 12 weeks) were included. Cannabis exposure was ascertained by urine immunoassay for 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH); positive results were confirmed with liquid chromatography tandem mass spectrometry. The primary outcome was moderate-to-severe nausea by the PUQE score. Overall, 9,250 participants were included, and 5.8% (95% CI 5.4-6.3%) had detectable urine THC-COOH. In adjusted analyses, higher THC-COOH levels were associated with greater odds of moderate-to-severe nausea (20.7% in the group with THC-COOH detected vs 15.5% in the group with THC-COOH not detected, adjusted odds ratio 1.6, 95% CI 1.1-2.2 for a 500 ng/mg Cr THC-COOH increment).
  • Thumbnail Image
    Item
    Challenging the catechism of therapeutics for chronic neuropathic pain: targeting CaV2.2 interactions with CRMP2 peptides
    (Elsevier, 2013-12-17) Feldman, Polina; Khanna, Rajesh; Department of Pharmacology and Toxicology, IU School of Medicine
    Chronic neuropathic pain management is a worldwide concern. Pharmaceutical companies globally have historically targeted ion channels as the therapeutic catechism with many blockbuster successes. Remarkably, no new pain therapeutic has been approved by European or American regulatory agencies over the last decade. This article will provide an overview of an alternative approach to ion channel drug discovery: targeting regulators of ion channels, specifically focusing on voltage-gated calcium channels. We will highlight the discovery of an anti-nociceptive peptide derived from a novel calcium channel interacting partner – the collapsin response mediator protein 2 (CRMP2). In vivo administration of this peptide reduces pain behavior in a number of models of neuropathic pain without affecting sympathetic-associated cardiovascular activity, memory retrieval, sensorimotor function, or depression. A CRMP2-derived peptide analgesic, with restricted access to the CNS, represents a completely novel approach to the treatment of severe pain with an improved safety profile. As peptides now represent one of the fastest growing classes of new drugs, it is expected that peptide targeting of protein interactions within the calcium channel complex may be a paradigm shift in ion channel drug discovery.
  • Thumbnail Image
    Item
    Chimeric agents derived from the functionalized amino acid, lacosamide, and the α-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lacosamide and safinamide
    (American Chemical Society, 2015-02-18) Park, Ki Duk; Yang, Xiao-Fang; Dustrude, Erik T.; Wang, Yuying; Ripsch, Matthew S.; White, Fletcher A.; Khanna, Rajesh; Kohn, Harold; Department of Psychiatry, IU School of Medicine
    The functionalized amino acid, lacosamide ((R)-2), and the α-aminoamide, safinamide ((S)-3), are neurological agents that have been extensively investigated and have displayed potent anticonvulsant activities in seizure models. Both compounds have been reported to modulate voltage-gated sodium channel activity. We have prepared a series of chimeric compounds, (R)-7-(R)-10, by merging key structural units in these two clinical agents, and then compared their activities with (R)-2 and (S)-3. Compounds were assessed for their ability to alter sodium channel kinetics for inactivation, frequency (use)-dependence, and steady-state activation and fast inactivation. We report that chimeric compounds (R)-7-(R)-10 in catecholamine A-differentiated (CAD) cells and embryonic rat cortical neurons robustly enhanced sodium channel inactivation at concentrations far lower than those required for (R)-2 and (S)-3, and that (R)-9 and (R)-10, unlike (R)-2 and (S)-3, produce sodium channel frequency (use)-dependence at low micromolar concentrations. We further show that (R)-7-(R)-10 displayed excellent anticonvulsant activities and pain-attenuating properties in the animal formalin model. Of these compounds, only (R)-7 reversed mechanical hypersensitivity in the tibial-nerve injury model for neuropathic pain in rats.
  • Thumbnail Image
    Item
    Comparison of lidocaine-dexmedetomidine and lidocaine-saline on the characteristics of the modified forearm bier block: A clinical trial
    (Wolters Kluwer, 2021) Ghaderi, Kamal; Rahmani, Khaled; Rahmanpanah, Nasser; Shami, Shoaleh; Zahedi, Farhad; Nasseri, Karim; Medicine, School of Medicine
    Background and aims: Forearm Modified Bier Block (FMBB) reduces local anesthetic systemic toxicity risks compared to the traditional method. This study was designed and implemented to compare the effects of lidocaine-dexmedetomidine (LD) and lidocaine-saline (LS) on the characteristics of the MFBB in distal forearm and hand surgery. Material and methods: In this randomized double-blind trial, which was conducted after obtaining institutional ethical committee approval, 60 patients were enrolled and randomly divided into two groups. In both groups, the analgesic base of the block was 20 mL lidocaine 0.5% that was supplemented by 1 μg/kg dexmedetomidine in the LD group or 1 mL of 0.9% saline in the LS group. Patients were evaluated for the onset and duration of sensory block, time of the first request for postoperative analgesic, and analgesic request frequency during the first 24 h after surgery. Results: Sensory block onset in the LD group (7.1 ± 1.4 min) compared to the LS group (8.4 ± 1.4) was faster (P = 0.008). Duration of the sensory block in LD group (49.7 ± 7.2 min) was longer than LS group (33.3 ± 2.6) (P < 0.001). Compared to LS group, time of the first request for postoperative analgesic in LD group was later (P = 0.6), and had lesser analgesic requests during the first 24 h after surgery (P < 0.001). Conclusion: Based on our study's finding, adding dexmedetomidine to lidocaine in the MFBB increases the duration of sensory block.
  • Thumbnail Image
    Item
    Effectiveness of maturity of Rubus occidentalis on hyperalgesia induced by acidic saline injection in rats
    (BMC, 2022) Choi, Geun Joo; Kang, Hyun; Lee, Oh Haeng; Ahn, Eun Jin; White, Fletcher A.; Cho, Ye Jin; Baek, Chong Wha; Jung, Yong Hun; Kwon, Ji Wung; Anesthesia, School of Medicine
    Background: Rubus occidentalis, also known as black raspberry, contains several bioactive components that vary depending on the maturity of the fruit. The goal of this study was to evaluate the efficacy of immature Rubus occidentalis extract(iROE) on acid-induced hyperalgesia, investigate the mechanism involved, and compare the antihyperalgesic effect of immature and mature ROEs. Methods: In adult male Sprague-Dawley rats, chronic muscle pain was induced via two injections of acidic saline into one gastrocnemius muscle. To evaluate the dose response, the rats were injected intraperitoneally with 0.9% saline or iROE (10, 30, 100, or 300 mg/kg) following hyperalgesia development. To evaluate the mechanism underlying iROE-induced analgesia, the rats were injected intraperitoneally with saline, yohimbine 2 mg/kg, dexmedetomidine 50 μg/kg, prazosin 1 mg/kg, atropine 5 mg/kg, mecamylamine 1 mg/kg, or naloxone 5 mg/kg 24 h after hyperalgesia development, followed by iROE 300 mg/kg administration. To compare immature versus mature ROE, the rats were injected with mature ROE 300 mg/kg and immature ROE 300 mg/kg after hyperalgesia development. For all experiments, the mechanical withdrawal threshold(MWT) was evaluated using von Frey filaments before the first acidic saline injection, 24 h after the second injection, and at various time points after drug administration. Data were analysed using multivariate analysis of variance(MANOVA) and the linear mixed-effects model(LMEM). We compared the MWT at each time point using analysis of variance with the Bonferroni correction. Results: The iROE 300 mg/kg injection resulted in a significant increase in MWT compared with the control, iROE 30 mg/kg, and iROE 100 mg/kg injections at ipsilateral and contralateral sites. The iROE injection together with yohimbine, mecamylamine, or naloxone significantly decreased the MWT compared with iROE alone, whereas ROE together with dexmedetomidine significantly increased the MWT. According to MANOVA, the effects of immature and mature ROEs were not significantly different; however, the LMEM presented a significant difference between the two groups. Conclusions: Immature R. occidentalis showed antihyperalgesic activity against acid-induced chronic muscle pain, which may be mediated by the α2-adrenergic, nicotinic cholinergic, and opioid receptors. The iROE displayed superior tendency regarding analgesic effect compared to mature ROE.